MILLTRUST INTERNATIONAL
 

OMass Therapuetics raises £27.5M in additional Series A

May 14, 2020

BY Alexander Kalis
MANAGING PARTNER

OMass Therapuetics, a drug discovery platform that harnesses mass spectrometry, raised £27.5M in additional Series A financing for a record total £42M round. Milltrust British Innovation Fund investee company Oxford Sciences Innovation, led the round along with Syncona. The funds will allow OMass to progress its pipeline of small molecule therapeutics for patients suffering with immunological and genetic disorders.